The estimated Net Worth of Edward M Basile is at least $3.5 Milion dollars as of 6 August 2024. Mr. Basile owns over 6,750 units of TransMedics stock worth over $1,075,986 and over the last 5 years he sold TMDX stock worth over $2,383,868. In addition, he makes $39,167 as Independent Director at TransMedics.
Edward has made over 7 trades of the TransMedics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 6,750 units of TMDX stock worth $189,810 on 6 August 2024.
The largest trade he's ever made was buying 8,500 units of TransMedics stock on 6 May 2019 worth over $136,000. On average, Edward trades about 3,271 units every 160 days since 2019. As of 6 August 2024 he still owns at least 7,482 units of TransMedics stock.
You can see the complete history of Mr. Basile stock trades at the bottom of the page.
Edward M. Basile serves as Independent Director of the Company. He is currently retired. During his 25 year tenure with the law firm King & Spalding, Mr. Basile served as Chair of the firm’s FDA and Life Sciences Practice and on the firm’s Policy and Compensation Committees. Mr. Basile’s law practice included representing large, medium and small medical device, pharmaceutical, and biotechnology companies before the U.S. Food and Drug Administration. Mr. Basile also served in the Chief Counsel’s Office of FDA as Associate Chief Counsel for Drugs & Biologics and Associate Chief Counsel for Enforcement from 1975 to 1985. Mr. Basile received a BSME from Lafayette College and a JD from George Washington University Law School. Basile’s decades of experience representing medical device, pharmaceutical and biotechnology companies qualify him to serve on our board of directors.
As the Independent Director of TransMedics, the total compensation of Edward Basile at TransMedics is $39,167. There are 9 executives at TransMedics getting paid more, with Waleed Hassanein having the highest compensation of $3,159,300.
Edward Basile is 72, he's been the Independent Director of TransMedics since 2016. There are 1 older and 15 younger executives at TransMedics. The oldest executive at TransMedics Group, Inc. is James Tobin, 75, who is the Independent Chairman of the Board.
Edward's mailing address filed with the SEC is C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810.
Over the last 5 years, insiders at TransMedics have traded over $99,976,312 worth of TransMedics stock and bought 154,333 units worth $3,250,328 . The most active insiders traders include Edwin M Jr Kania, Waleed H Hassanein oraz James R Tobin. On average, TransMedics executives and independent directors trade stock every 10 days with the average trade being worth of $2,982,476. The most recent stock trade was executed by Tamer I Khayal on 3 September 2024, trading 2,960 units of TMDX stock currently worth $98,065.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics executives and other stock owners filed with the SEC include: